Sanofi (NASDAQ:SNY) Position Increased by SG Americas Securities LLC

SG Americas Securities LLC increased its holdings in Sanofi (NASDAQ:SNY - Free Report) by 57.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,411 shares of the company's stock after buying an additional 10,403 shares during the quarter. SG Americas Securities LLC's holdings in Sanofi were worth $1,576,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its stake in Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after acquiring an additional 5,091,304 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Sanofi during the 4th quarter valued at approximately $135,933,000. Boston Partners lifted its position in Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the period. Magnetar Financial LLC lifted its stake in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after purchasing an additional 1,705,148 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in Sanofi by 969.6% in the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after purchasing an additional 861,770 shares during the period. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Down 0.5%

NASDAQ:SNY traded down $0.26 during trading hours on Monday, hitting $49.41. The stock had a trading volume of 1,945,550 shares, compared to its average volume of 2,380,131. The business has a 50 day simple moving average of $51.49 and a two-hundred day simple moving average of $52.06. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a market cap of $121.18 billion, a PE ratio of 19.84, a price-to-earnings-growth ratio of 1.01 and a beta of 0.50.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period last year, the firm earned $1.78 earnings per share. The company's revenue was down 11.0% on a year-over-year basis. Analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were paid a $2.0369 dividend. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is currently 56.79%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SNY. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. Finally, BNP Paribas began coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Sanofi has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.